FDA approves Global Blood Therapeutics’ drug targeting root cause of sickle cell disease
The agency gave accelerated approval to GBT's Oxbryta (voxelotor) for sickle cell disease in patients aged 12 and older. The drug works by inhibiting sickle hemoglobin polymerization.